Author

Arjan Bredenoord 1

1 Department Of Gastro

A novel budesonide orodispersible tablet formulation is highly effective to maintain endoscopic inflammatory remission and even complete endoscopic remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Luc Biedermann, Alfredo J. Lucendo, Stephan Miehlke, Christoph Schlag, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen E. Attwood, Alex Straumann

A novel oral budesonide formulation is highly effective for induction of remission in patients with active eosinophilic esophagitis: Results from the 6-weeks open-label treatment phase of EOS-2 trial

Alfredo J. Lucendo, Christoph Schlag, Stephan Miehlke, Luc Biedermann, Cecilio Santander Vaquero, Dirk Hartmann, Jamal Hayat, Petr Hruz, Constanza Ciriza De Los Ríos, Arjan Bredenoord, Michael Vieth, Ralph Müller, Roland Greinwald, Alex Straumann

A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE

Joachim Labenz, Philipp Schreiner, Ekaterina Safroneeva, Marcus Auth, Peter Bonis, Alain M. Schoepfer, Luc Biedermann, Arjan Bredenoord, Thomas Greuter, Joy W. Chang, Nirmala Gonsalves, Marc E. Rothenberg, Sandeep Gupta, David A Katzka, Margaret H. Collins, Alex Straumann, Evan S. Dellon, Glenn Furuta

Belching and aerophagia

Arjan Bredenoord

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Luc Biedermann, Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Michael Vieth, Christoph Schlag, Cecilio Santander, Constanza Ciriza de Los Rios, Christoph Schmöcker, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Stefan Schubert, Ralph Mueller, Roland Greinwald, Alain M. Schoepfer, Stephe

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Ralph Mueller, Christoph Schlag, Christoph Schmöcker, Roland Greinwald, Luc Biedermann, Michael Vieth, Alfredo J. Lucendo, Cecilio Santander, Alex Straumann, Petr Hruz, Ahmed Madisch, Stephan Miehlke, Stephen E. Attwood, Arjan Bredenoord, Stefan Schubert, Constanza Ciriza De Los Ríos, Alain M. Schoepfer, Jamal Hayat, Ulri

Budesonide orodispersible tablets are superior to maintain and even further improve quality of life in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Christoph Schlag, Luc Biedermann, Alfredo J. Lucendo, Stephan Miehlke, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen E. Attwood, Alex Straumann

Budesonide orodispersible tablets are superior to maintain combined clinical and histological remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Michael Vieth, Christoph Schlag, Luc Biedermann, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Stefan Schubert, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen

CLINICAL AND ENDOSCOPIC CHARACTERISTICS CAN HELP DISTINGUISH PSEUDOACHALASIA FROM ACHALASIA

Fraukje Anna-marie Ponds, Ingmar Van Raath, André Smout, Arjan Bredenoord

Clinical presentation and epidemiology

Arjan Bredenoord

Item 1 - 10 / 86
1
2 3 4 5 6 7 8 9